Aadi Bioscience Inc expected to post a loss of 22 cents a share - Earnings Preview

Whitehawk Therapeutics

07/03/2025 12:34

Aadi Bioscience Inc AADI.OQ AADI.O is expected to show a rise in quarterly revenue when it reports  results on March 11 (estimated) for the period ending December 31 2024

The Pacific Palisades California-based  company is expected to report a 17.8% increase in revenue to $7.45 million from $6.33 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aadi Bioscience Inc is for a loss of 22 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aadi Bioscience Inc is $3.00​, above​ its last closing price of $2.10. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.38
-0.46
-0.46
Met
-0.5
Jun. 30 2024
-0.69
-0.69
-0.54
Beat
21.7
Mar. 31 2024
-0.63
-0.64
-0.68
Missed
-5.8​
Dec. 31 2023
-0.65
-0.60
Beat
7.4
​​Sep. 30 2023
-0.72
-0.72
-0.60
Beat
17.1
Jun. 30 2023
-0.61
-0.62
-0.67
Missed
-7.7​
Mar. 31 2023
-0.58
-0.58
-0.57
Beat
2.4
Dec. 31 2022
-0.71
-0.52
Beat
26.8

This summary was machine generated March 7 at 12:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)